Impact Biomedical (IBO) Income from Non-Controlling Interests (2022 - 2026)
Impact Biomedical (IBO) posted Income from Non-Controlling Interests of $3000.0 for Q1 2026, up 160.0% on a QoQ basis from -$5000.0 in Q3 2025, and up 127.27% year-over-year from $1320.0 in Q1 2025.
Impact Biomedical (IBO) Income from Non-Controlling Interests (2022 - 2026) Analysis & Trends
Impact Biomedical's Income from Non-Controlling Interests history runs 5 years deep, the most recent figure standing at $3000.0 for Q1 2026.
- Quarterly Income from Non-Controlling Interests rose 127.27% year-over-year to $3000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$19000.0 (up 48.65% YoY) and the FY2024 annual result came in at -$62000.0, up 12.68% from the prior year.
- Income from Non-Controlling Interests was $3000.0 for Q1 2026 at Impact Biomedical, up from -$5000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $200000.0 in Q4 2022 and bottomed at -$192000.0 in Q1 2023.
- A 5-year average of -$17800.0 and a median of -$15000.0 in 2023 frame the typical range for Income from Non-Controlling Interests.
- Annual changes were most pronounced in 2025 — Income from Non-Controlling Interests plunged 220.0% — and 2026, when it surged 127.27%.
- Impact Biomedical's Income from Non-Controlling Interests stood at $200000.0 in 2022, then slumped by 113.0% to -$26000.0 in 2023, then grew by 3.85% to -$25000.0 in 2024, then surged by 80.0% to -$5000.0 in 2025, then soared by 160.0% to $3000.0 in 2026.
- Business Quant data shows IBO's Income from Non-Controlling Interests at $3000.0 in Q1 2026, -$5000.0 in Q3 2025, and -$6000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Impact Biomedical | 47.44 Mn | 50.67 Mn | - | 3,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3,000.00 |
| Sep 30, 2025 | -5,000.00 |
| Jun 30, 2025 | -6,000.00 |
| Mar 31, 2025 | -11,000.00 |
| Dec 31, 2024 | -25,000.00 |
| Sep 30, 2024 | -6,000.00 |
| Jun 30, 2024 | 5,000.00 |
| Mar 31, 2024 | -36,000.00 |
| Dec 31, 2023 | -26,000.00 |
| Sep 30, 2023 | -15,000.00 |
| Jun 30, 2023 | -19,000.00 |
| Mar 31, 2023 | -192,000.00 |
| Dec 31, 2022 | 200,000.00 |
| Sep 30, 2022 | -67,000.00 |
| Jun 30, 2022 | -67,000.00 |